B3GNT3: A prognostic biomarker associated with immune cell infiltration in pancreatic adenocarcinoma

Kong, Kaiwen; Zhao, Yuanyu; Xia, Leilei; Jiang, Hui; Xu, Man; Zheng, Jianming

doi:10.3892/ol.2020.12420

Cited by 5 publications

(5 citation statements)

References 30 publications

(35 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The levels of B3GNT3 protein were determined using the HPA database and western blot, indicating higher expression in LUAD tissues and LUAD cells than in normal lung tissues and human bronchial epithelial cells, respectively. Consistent with our findings, B3GNT3 was revealed as a carcinogenic factor by presenting higher expression in pancreatic cancer (16), early-stage cervical cancer (15), neuroblastoma (14), and endometrial cancer tissues than in normal tissues (29). In our study, high levels of B3GNT3 were associated with poor prognosis with advanced stage and higher mortality rates, which was also indicated in previous lung cancer (19) and non-small cell lung cancer studies (12).…”

Section: Discussionsupporting

confidence: 92%

“…B3GNT3, Beta-1,3-N-acetylglucosaminyltransferase 3, is a type II transmembrane protein located in the Golgi apparatus and is essential for forming extended core 1 oligosaccharides (10,11). Numerous studies have reported the involvement of B3GNT3 in malignant transformation and B3GNT3 expression is strongly correlated with PD-L1 levels and EGFR mutation status (12)(13)(14)(15)(16)(17)(18)(19). It has been indicated that B3GNT3 expression is strongly correlated with PD-L1 levels and EGFR mutation status.…”

Section: Introductionmentioning

confidence: 99%

“…High expression of B3GNT3 is associated with advanced histologic grade and poorer OS. However, in neuroblastoma B3GNT3 expression inhibits cell migration and invasion and predicts favorable outcomes (14). It has been determined that the tumor-infiltrating immune cells are correlated with the development, progression and prognosis of LUAD (20).…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

B3GNT3 as a prognostic biomarker and correlation with immune cell infiltration in lung adenocarcinoma

Wu¹,

Luo²,

Li³

et al. 2022

Ann Transl Med

View full text Add to dashboard Cite

Background: Lung adenocarcinoma (LUAD) is the most common malignant cancer in humans and because of low long-term survival rates, exploration of the molecular mechanisms underlying its progression, as well as novel prognostic predictors, is urgently needed. B3GNT3, a type II transmembrane protein located in the Golgi apparatus, is essential for forming extended core 1 oligosaccharides and is reportedly involved in malignant transformation. Methods:The Cancer Genome Atlas (TCGA) and GSE68465 were used to analyze the expression of B3GNT3 in LUAD and normal tissues and overall survival. Real time quantitative polymerase chain reaction (qPCR) and western blot were conducted to measure the mRNA and protein levels of B3GNT3, respectively. Functional enrichment of differentially expressed genes was explored using Gene Ontology and Kyoto Encyclopedia of Genes and Genomes pathway analyses. We performed univariate and multivariate Cox regression analyses and a meta-analysis to reveal an independent factor for LUAD. We evaluated the correlation between immune infiltration levels and cumulative survival in the TIMER database. The correlation between B3GNT3 and immune cell infiltration was assessed via Cell-type Identification by Estimating Relative Subsets of RNA Transcripts (CIBERSORT). The association of DNA methylation of B3GNT3 and prognosis was determined. A nomogram that incorporated expression and clinical features was additionally built for prognostic prediction. Cell proliferation, cloning, and invasion were conducted to validate the roles of B3GNT3 in LUAD.Results: B3GNT3 was more highly expressed in LUAD tissues than in normal lung tissues, consistent with the mRNA and protein levels in LUAD cells. B3GNT3 was an independent factor for LUAD. Moreover, the levels of B3GNT3 were related to immune cell infiltration in LUAD microenvironments. DNA methylation of B3GNT3 correlated with the mRNA of B3GNT and overall survival of LUAD patients. The expression of B3GNT3 was highly valuable for the prediction of diagnosis. Knockdown of B3GNT3 inhibited LUAD cell viability and cloning ability, and hindered invasion.Conclusions: B3GNT3 was highly associated with immune cell infiltration, acting as an important biomarker for the prognosis and diagnosis of LUAD.

show abstract

Section: Discussionsupporting

confidence: 92%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

B3GNT3 as a prognostic biomarker and correlation with immune cell infiltration in lung adenocarcinoma

Wu¹,

Luo²,

Li³

et al. 2022

Ann Transl Med

View full text Add to dashboard Cite

show abstract

“…B3GNT3 is a type II transmembrane protein located in the Golgi apparatus. It is involved in the biosynthesis of the polyacetamide chain, generation of principal components of dimeric sialic acid Lewis A, regulation of l-selectin ligand function, lymphocyte trafficking and attribution of T cells (19)(20)(21)(22). The B3GNT3 gene is located on chromosome 19q13.1 and belongs to the β3GlcNAcT gene family, which contains at least 8 different β3GlcNAcT genes.…”

Section: Discussionmentioning

confidence: 99%

Experimental study on the suppressive effect of B3GNT3 on the apoptosis of lung adenocarcinoma cells and its application in early screening for lung adenocarcinoma

Shuai¹,

Peng²,

Lv³

et al. 2023

J Thorac Dis

View full text Add to dashboard Cite

Background: Lung adenocarcinoma, as a common histological type in lung cancer, the overall survival is very low, and the prognosis is poor because it is difficult to find and easily recurs. Therefore, this study aimed to explore the role of the secreted protein beta-1,3-N-acetylglucosaminyltransferase 3 (B3GNT3) in the development of lung adenocarcinoma and to evaluate its potential significance for early clinical biomarker screening. Methods:The mRNA expression profiles of patients with lung adenocarcinoma and normal controls were analyzed via The Cancer Genome Atlas (TCGA) database. Serum samples of clinical lung cancer patients and healthy people were obtained, and the differences in B3GNT3 expression in different stages of lung adenocarcinoma and in healthy tissues were compared. Kaplan-Meier (K-M) curves were drawn to clarify the influence of high and low expression of B3GNT3 on the prognosis of patients. Peripheral blood samples from patients with lung adenocarcinoma and healthy people were obtained clinically, and receiver operating characteristic (ROC) curves were drawn to clarify the sensitivity and specificity of B3GNT3 expression for the diagnosis of lung adenocarcinoma. Lung adenocarcinoma cells were cultured in vitro, the expression of B3GNT3 was knocked down by lentivirus infection. The expression of the apoptosis-associated genes was detected by reverse transcription-polymerase chain reaction (RT-PCR). Results:The secreted protein B3GNT3 is significantly differentially expressed in the serum of patients with lung adenocarcinoma versus normal controls. Subgroup analysis according to lung adenocarcinoma clinical stage showed that the higher the clinical stage of lung adenocarcinoma was, the higher the B3GNT3 expression. Enzyme-linked immunosorbent assay (ELISA) revealed that B3GNT3 expression was significantly increased in the serum of patients with lung adenocarcinoma and significantly decreased after surgery. By inhibiting programmed cell death-ligand 1 (PD-L1), the level of apoptosis was significantly increased and the proliferative capacity was significantly inhibited. In contrast, the level of apoptosis was significantly increased and the proliferation ability was significantly inhibited after simultaneous overexpression of B3GNT3 and inhibition of PD-L1.Conclusions: High expression of the secreted protein B3GNT3 in lung adenocarcinoma is closely related to prognosis and can serve as a potential biological marker for the early screening of lung adenocarcinoma.

show abstract

“…It mainly plays tumor-promoting activity in various types of tumors, including pancreatic [58,59], cervical [60], endometrial [61], and lung cancer [62,63]. In some instances, the expression of B3GNT3 inhibits the anti-cancer immune response, as in pancreatic [64], breast [65] and lung cancer [66]. In particular, in triple negative breast cancer, B3GNT3 promotes through EGFR the interaction between PD-1 and PD-L1, resulting in This reaction is mediated by different B3GNTs, specific to several types of sugar chains (e.g., type 2 chains for B3GNT4 and B3GNT7, glycolipids for B3GNT5, O-linked for B3GNT9).…”

Section: Polylactosaminic Chainsmentioning

confidence: 99%

Glycosyltransferases in Cancer: Prognostic Biomarkers of Survival in Patient Cohorts and Impact on Malignancy in Experimental Models

Pucci

Duca

Malagolini

et al. 2022

Cancers

View full text Add to dashboard Cite

Background: Glycosylation changes are a main feature of cancer. Some carbohydrate epitopes and expression levels of glycosyltransferases have been used or proposed as prognostic markers, while many experimental works have investigated the role of glycosyltransferases in malignancy. Using the transcriptomic data of the 21 TCGA cohorts, we correlated the expression level of 114 glycosyltransferases with the overall survival of patients. Methods: Using the Oncolnc website, we determined the Kaplan–Meier survival curves for the patients falling in the 15% upper or lower percentile of mRNA expression of each glycosyltransferase. Results: Seventeen glycosyltransferases involved in initial steps of N- or O-glycosylation and of glycolipid biosynthesis, in chain extension and sialylation were unequivocally associated with bad prognosis in a majority of cohorts. Four glycosyltransferases were associated with good prognosis. Other glycosyltransferases displayed an extremely high predictive value in only one or a few cohorts. The top were GALNT3, ALG6 and B3GNT7, which displayed a p < 1 × 10−9 in the low-grade glioma (LGG) cohort. Comparison with published experimental data points to ALG3, GALNT2, B4GALNT1, POFUT1, B4GALT5, B3GNT5 and ST3GAL2 as the most consistently malignancy-associated enzymes. Conclusions: We identified several cancer-associated glycosyltransferases as potential prognostic markers and therapeutic targets.

show abstract

B3GNT3: A prognostic biomarker associated with immune cell infiltration in pancreatic adenocarcinoma

Cited by 5 publications

References 30 publications

B3GNT3 as a prognostic biomarker and correlation with immune cell infiltration in lung adenocarcinoma

B3GNT3 as a prognostic biomarker and correlation with immune cell infiltration in lung adenocarcinoma

Experimental study on the suppressive effect of B3GNT3 on the apoptosis of lung adenocarcinoma cells and its application in early screening for lung adenocarcinoma

Glycosyltransferases in Cancer: Prognostic Biomarkers of Survival in Patient Cohorts and Impact on Malignancy in Experimental Models

Contact Info

Product

Resources

About